FDA Legalization Progress
On September 29, 2025, the U.S. Food and Drug Administration (FDA) formally confirmed NMN as a legal ingredient for dietary supplements, concluding nearly three years of regulatory uncertainty. This decision, driven by sustained advocacy from the Natural Products Association (NPA) and judicial interpretation of market access provisions, permits NMN's return to the supplement market.
New Clinical Research Breakthroughs
Cardiovascular Protection: Sinolink Pharmaceuticals demonstrated efficacy in treating diabetic eye diseases, while its potential therapeutic value for cardiovascular conditions is under development.
Anti-Aging Mechanisms: Jiangsu University discovered NMN-combined exosome experiments effectively resist skin aging; Nanchang University research indicated that boosting NAD+ may counteract glaucoma.
